PBS Biotech
PrivateLast Round
Growth Equity
Jan 6, 2025
Est. Valuation
$224.5M
Total Funding Raised
$49M
Company Overview
PBS Biotech operates in Healthcare & Life Sciences and is based in Camarillo, California. Its latest recorded funding round was a Growth Equity round in January 2025.
PBS Biotech is a biotechnology company that manufactures single-use bioreactor systems and provides process development services for the cell therapy industry.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PBS Biotech Comparables
Compare PBS Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eppendorf SE | 78% | |
| OmniBRx Biotechnologies | 76% | |
| Danaher | 74% |
For institutional investors. Book with your work email.
PBS Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Jan 6, 2025 | ||||
| VC Round | Sep 11, 2024 | ||||
| Series B | Jan 9, 2023 | ||||
| Series A | Aug 16, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
PBS Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Growth Equity, VC Round, Series B |
| BroadOak Capital Partners | Growth Equity, VC Round, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 26, 2026
Monthly visitors grew 101% MoM.
- May 4, 2025
Monthly visitors increased 68% MoM, reaching 3.2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- adopts_technologyOct 5, 2026
PBS Biotech, Inc. uses Rockwell Automation technology embedded in its MiniPRO multi-parallel bioreactor platform to automate process control and support the transfer of cell therapy development processes toward clinical and commercial manufacturing.
- partners_withSep 29, 2026
PBS Biotech, Inc. partnered with Rockwell Automation, Inc. to embed standardized automation into its MiniPRO platform, enabling parallel cell therapy process development and scalable manufacturing, announced in Wisconsin on Sep 29th '26.
For institutional investors. Book with your work email.
PBS Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PBS Biotech's valuation, stock price, and market status.
Is PBS Biotech a public or private company?
PBS Biotech is a private company.
What is the current stock price of PBS Biotech?
PBS Biotech is a private company, so its shares have no public market price. Caplight tracks PBS Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PBS Biotech worth (valuation)?
PBS Biotech's valuation is estimated at $224.5M based on funding round data.
Can I buy PBS Biotech stock?
PBS Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PBS Biotech's last funding round?
PBS Biotech's most recent funding round was Growth Equity on January 6, 2025.
Who are the main investors in PBS Biotech?
Key investors in PBS Biotech include Avego Management, BroadOak Capital Partners.
Will PBS Biotech IPO soon?
No public IPO plans have been announced for PBS Biotech.
How can I track PBS Biotech secondary market activity?
Caplight tracks bids, offers, and trades in PBS Biotech's shares on secondary markets.